CITATION REPORT List of articles citing

Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension

DOI: 10.1111/cts.12382 Clinical and Translational Science, 2016, 9, 29-35.

Source: https://exaly.com/paper-pdf/64429524/citation-report.pdf

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
5	Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report). <i>Clinical Drug Investigation</i> , 2018 , 38, 219-229	3.2	3
4	Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis. <i>Clinical Drug Investigation</i> , 2019 , 39, 1031-1044	3.2	4
3	Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020	94352	33
2	[Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia]. <i>Terapevticheskii Arkhiv</i> , 2020 , 92, 80-85	0.9	5
1	Changes in CYP3A4 Enzyme Expression and Biochemical Markers Under Acute Hypoxia Affect the Pharmacokinetics of Sildenafil <i>Frontiers in Physiology</i> , 2022 , 13, 755769	4.6	0